All News
ICYMI: Introducing Polyrefractory RA: A New Frontier in Difficult-to-Treat RA
At a EULAR 2025 session titled “What makes ‘Difficult-to-treat RA’ so difficult to treat? And what can we do?”, Drs. Paula David and Dennis McGonagle introduced the emerging concept of polyrefractory rheumatoid arthritis (RA), a term now being used to describe a subset of patients who have failed to respond to five or more biologic or targeted synthetic DMARDs. This new classification, derived from recent multinational registry data, represents a significant step in refining our understanding and management of the most treatment-resistant forms of RA.
Read Article
PCR: Prevalence, Cost, & Risk (6.27.2025)
Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com
Read Article
ARD's Impact Factor
EULAR
Annals of the Rheumatic Diseases (ARD) is the official journal of EULAR –The European Alliance of Associations for Rheumatology. An international peer-reviewed publication committed to promoting the highest standards of scientific exchange and education.
JAK Inhibitors: The Latest from the JAK-pot Study
Dr. David Liew reports on abstract POS0150 - Evolution of Janus Kinase Inhibitors (JAKi) Prescriptions Since 2015 In An International Collaboration of Rheumatoid Arthritis Registers (The 'JAK-pot' Study): Effect of Regulatory https://t.co/KiOZuphQTx
Dr. John Cush RheumNow ( View Tweet)
AI Advances axSpA Diagnosis with Multimodal MRI
Dr. Bella Mehta reports on abstract OP0307 presented at the 2025 EULAR meeting in Barcelona, Spain.
https://t.co/fpgwQniSA5 https://t.co/EbT9v821xb
Dr. John Cush RheumNow ( View Tweet)
Complex-to-Manage PsA: The GRAPPA Framework and Definition
Dr. Nelly Ziade discusses abstract OP0175 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/cyDUCGU6Pc https://t.co/jdsTEB3Rqw
Links:
Dr. John Cush RheumNow ( View Tweet)
All Rheumatoid Arthritis is Not the Same
Dr. Jonathan Kay reviews abstracts OP0323 and OP0328 from the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/rbK3Y1NHVI https://t.co/eYPdbx87kt
Links:
Dr. John Cush RheumNow ( View Tweet)
Assessment of Peripheral Arthritis in Spondyloarthritis
Dr. Antoni Chan talks with Dr. Dafne Capelusnik about abstract POS0257 presented at the 2025 EULAR meeting in Barcelona.
https://t.co/E6l6qvNnox https://t.co/gLbMjF406q
Dr. John Cush RheumNow ( View Tweet)
Resilience or Resignation? Rethinking Pain, Aging, and Quality of Life
Dr. Jiha Lee reports on abstract POS0402 - THE ROLE OF AGEING IN THE RELATIONSHIP BETWEEN CHRONIC MUSCULOSKELETAL PAIN AND HEALTH-RELATED QUALITY OF LIFE: THE MAASTRICHT STUDY - presented at the 2025 EULAR https://t.co/AiP57hXIRB
Dr. John Cush RheumNow ( View Tweet)
GRAPPA vs. EULAR on Complex/Difficult-to-Manage Psoriatic Arthritis
Following the establishment of formal definitions for Difficult-to-Treat Rheumatoid Arthritis (D2T RA) by EULAR and Difficult-to-Manage axial Spondyloarthritis (D2M axSpA) by ASAS, the “Difficult” framework has https://t.co/NYgivNRgUV
Dr. John Cush RheumNow ( View Tweet)
Trends and Innovations from Barcelona (6.20.2025)
Dr. Jack Cush reviews highlights, trends and novel studies from EULAR 2025 in Barcelona from last week.
https://t.co/iEiQI8GACt https://t.co/X27CuZb5wH
Dr. John Cush RheumNow ( View Tweet)
AI in Early Diagnosis of Giant Cell Arteritis
Dr. Bella Mehta reviews abstract OP0343 - THE CLAUDICAITIO MODEL: ULTRASOUND IMAGE CLASSIFICATION IN GIANT CELL ARTERITIS BY APPLICATION OF ARTIFICIAL INTELLIGENCE - at the 2025 EULAR meeting in Barcelona.
https://t.co/lJFuAgmSTH https://t.co/R1tbYpJ74o
Links:
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Arthritis Panel: EULAR 2025
Panelists Drs. Mrinalini Dey, Janet Pope, Jonathan Kay and Jack Cush review RA studies and sessions presented at the 2025 EULAR meeting in Barcelona, Spain. Abstracts discussed: OP0004; OP0105; LB0006; OP0327; OP0330; OP0232; 0P0190. https://t.co/hmosUKOgTt
Dr. John Cush RheumNow ( View Tweet)
IL-17 inhibitors - Long-term Extensions and Uveitis
Dr. Peter Nash offers his perspective on data presented at the 2025 EULAR meeting in Barcelona.
https://t.co/eQd0TcQn76 https://t.co/6Zog4LC8Aj
Links:
Dr. John Cush RheumNow ( View Tweet)
There's an App for That (and it works): the AXIA RCT
Dr. Aurelie Najm reports on abstract LB0002 presented at the EULAR 2025 meeting in Barcelona, Spain.
https://t.co/IRZ1L7BqLW https://t.co/Av2vVheShE
Links:
Dr. John Cush RheumNow ( View Tweet)
Promising role of Fc neonatal receptor blockade in autoimmune rheumatic diseases
During the Late-Breaking Abstract session at EULAR 2024, we learned about a novel mechanism of action therapy, nipocalimab in Sjogren’s disease (SjD).
https://t.co/5bjyaqTqSN https://t.co/i4mGMYfyNK
Dr. John Cush RheumNow ( View Tweet)
National Psoriasis Found. Consensus Defines On-Treatment Remission in Plaque Psoriasis as 0% BSA and MD global=0 for at least 6 months while on treatment. For both clinical practice and clinical trials. https://t.co/QJg0ZIQ5Mv https://t.co/0FnbFcpXQB
Links:
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – RA Panel Discussion
Leading experts in rheumatology dive into the latest advances, treatment strategies, and emerging research in rheumatoid arthritis. Don’t miss this in-depth panel as they unpack key findings from EULAR 2025 and discuss what’s next for RA care. https://t.co/hoxz0zWieN
Dr. John Cush RheumNow ( View Tweet)
Eular 2025 PsA Topic Panel
https://t.co/wJ08aKGZfJ https://t.co/6OvkIeOT76
Dr. John Cush RheumNow ( View Tweet)
EULAR 2025 – SpA Panel Discussion
Leading rheumatology experts discuss the latest research, treatment advances, and clinical insights in axial spondyloarthritis. Hear what’s new from EULAR 2025 and what it means for improving patient outcomes.
https://t.co/AcwtseWBi0 https://t.co/MzEN0VtLx6
Dr. John Cush RheumNow ( View Tweet)
